Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;398(9):12421-12431.
doi: 10.1007/s00210-025-04041-x. Epub 2025 Mar 28.

FOXA1-mediated transcription of MFAP2 facilitates cell growth, metastasis and cisplatin resistance in uterine corpus endometrial carcinoma

Jie Bai  1   2 , Jing Bai  3 , Hongzhen Zhang  4
Affiliations

FOXA1-mediated transcription of MFAP2 facilitates cell growth, metastasis and cisplatin resistance in uterine corpus endometrial carcinoma

Jie Bai et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Sep.

Abstract

Microfibril-associated protein 2 (MFAP2) has been confirmed to be an oncogene to participate in regulating the progression of many cancers. However, its role and mechanism in the development of uterine corpus endometrial carcinoma (UCEC) are still unclear. The mRNA and protein levels of MFAP2 and forkhead box A1 (FOXA1) were determined using qRT-PCR and western blot. Cell proliferation, apoptosis, migration, invasion and cisplatin resistance were detected by colony formation assay, EdU assay, flow cytometry, transwell assay and CCK8 assay. Xenograft tumor models were constructed to explore the effect of MFAP2 knockdown on UCEC tumorigenesis and cisplatin resistance in vivo. The interaction between FOXA1 and MFAP2 promoter was evaluated by ChIP assay and dual-luciferase reporter assay. MFAP2 was upregulated in UCEC tissues and cells. Silencing of MFAP2 repressed UCEC cell growth, metastasis and cisplatin resistance in vitro, as well as reduced tumorigenesis in vivo. In terms of mechanism, FOXA1 bound to MFAP2 promoter region to increase its expression. FOXA1 knockdown could inhibit UCEC cell growth, metastasis and cisplatin resistance. Moreover, FOXA1 promoted growth, metastasis and cisplatin resistance in UCEC cells via enhancing MFAP2 expression. FOXA1-activated MFAP2 might contribute to the growth, metastasis and cisplatin resistance of UCEC cells, providing a novel target for UCEC treatment.

Keywords: FOXA1; MFAP2; Uterine corpus endometrial carcinoma.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The present study was approved by the ethical review committee of the Affiliated Hospital of North China University of Science and Technology. Written informed consent was obtained from all enrolled patients. Patient consent for publication: The results presented in this paper have not been published preciously in whole or in part. Competing interests: The authors declare no competing interests.

References

    1. Adams EJ, Karthaus WR, Hoover E et al (2019) FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature 571:408–412. https://doi.org/10.1038/s41586-019-1318-9 - DOI - PubMed - PMC
    1. Cai J, Huang S, Yi Y et al (2019) Downregulation of PTPN18 can inhibit proliferation and metastasis and promote apoptosis of endometrial cancer. Clin Exp Pharmacol Physiol 46:734–742. https://doi.org/10.1111/1440-1681.13098 - DOI - PubMed
    1. Chen G, Wei RS, Ma J et al (2023) FOXA1 prolongs S phase and promotes cancer progression in non-small cell lung cancer through upregulation of CDC5L and activation of the ERK1/2 and JAK2 pathways. Kaohsiung J Med Sci 39:1077–1086. https://doi.org/10.1002/kjm2.12737 - DOI - PubMed - PMC
    1. Crosbie EJ, Kitson SJ, McAlpine JN et al (2022) Endometrial cancer. Lancet 399:1412–1428. https://doi.org/10.1016/S0140-6736(22)00323-3 - DOI - PubMed
    1. Ding N, Zhang H, Su S et al (2018) Emodin Enhances the Chemosensitivity of Endometrial Cancer by Inhibiting ROS-Mediated Cisplatin-resistance. Anticancer Agents Med Chem 18:1054–1063. https://doi.org/10.2174/1871520618666171219113036 - DOI - PubMed

MeSH terms

LinkOut - more resources